Drug search by name

Peginterferon Alfa-2b (Peg-Intron) and Bone marrow suppression

Result of checking the interaction of drug Peginterferon Alfa-2b (Peg-Intron) and disease Bone marrow suppression for safety when used together.

Check result:

Peginterferon Alfa-2b (Peg-Intron) <> Bone marrow suppression

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Peginterferons alfa suppress bone marrow function and may result in severe cytopenias. Very rarely, it may be associated with aplastic anemia. These drugs should be used with caution in patients with baseline neutrophil counts less than 1,500 cells/mm3, with platelet counts less than 90,000 cells/mm3 or baseline hemoglobin less than 10 g/dL. It is advised that complete blood counts be obtained pretreatment and monitored routinely during therapy. Neutropenia and thrombocytopenia occur with greater incidence in patients coinfected with HIV.

Peginterferon Alfa-2b (Peg-Intron)

Generic Name: peginterferon alfa-2b

Brand Name: PegIntron, Sylatron, PegIntron Redipen

Synonyms: Peginterferon alfa-2b, Peginterferon Alfa-2b

What is Peginterferon Alfa-2b (Peg-Intron)?